

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

HAVN Life Sciences Inc. (the “Company”)
Suite 2200, 885 Wet Georgia Street
Vancouver, BC V6C 3E8

Item 2 Date of Material Change

December 1, 2020

Item 3 News Release

A news release with respect to the contents of this report was issued on December 1, 2020 and was disseminated through the facilities of recognized newswire services. A copy of the news release was filed on SEDAR.

Item 4 Summary of Material Change

On December 1, 2020, the Company announced it has become a voting member of the Conservative Drug Policy Reform Group (CDPRG). It also announced that David King, director of research for CDPRG, has joined the Havn Life advisory board.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

On December 1, 2020, the Company announced it has become a voting member of the [Conservative Drug Policy Reform Group](#) (CDPRG).

The Company is also pleased to announce that David King, director of research for CDPRG, has joined the Havn Life advisory board. King has co-authored several CDPRG white papers including 'The UK Review of Medicinal Cannabis: The Needs of a Nation' and 'The Medicinal Use of Psilocybin: A call for reform.' This year, King received the Dr Abbas Khan Medal by King's College London for 'outstanding humanitarian contributions to the service of society'.

He is also a founder of the Breaking Convention, Europe's largest academic conference on psychedelic drug research, and was a founding director of the Breaking Convention charity from 2010 to 2019.

The CDPRG is a UK-based organization that assembles evidence from across the fields of medicine, law-enforcement, economics, ethics, criminology and human rights, for the benefit of drug policy-making. This year the CDPRG launched a campaign to reschedule psilocybin in the UK as part of their mission to provide greater access for research and medicinal purposes. Havn Life will commission 250 hours of work from CDPRG's researchers.

“Being a part of the CDPRG global network of scientists allows us to utilize multidisciplinary expertise to develop psilocybin protocols that can have global impact,” says Tim Moore, Havn Life CEO. “Collaboration across fields allows us to move the needle. We are building a strong foundation of knowledge to develop a safe and reliable supply of naturally-derived psychedelic compounds for research”.

“As the clinical trial evidence for psychedelic therapies grows, it becomes increasingly clear that these interventions are safe, well-tolerated, and have the potential to change lives for the better, sometimes after only a single session,” says King. “We do not yet know what the real-world impact of these therapies will be, but there are good reasons to believe that we will be better equipped to treat some of the most difficult and burdensome conditions of the modern age, for which new approaches are desperately needed.”

King completed his undergraduate degree in medical anthropology in 2011, with a research thesis on beliefs and attitudes to health, illness and medicine among cannabis-using populations. He has also worked as a researcher at the Beckley Foundation and in immunology at the National University of Singapore. King was the founding President of both the award-winning Psychedelics Society at the University of Kent and the Society for Psychedelic Studies at King's College London.

King first met Havn Life Chief Psychedelic Officer Dr. Ivan Casselman when they both were students together at the School of Anthropology and Conservation, University of Kent, over ten years ago.

“I am delighted to be working with Dr. Casselman and the other members of the Havn Life team as they move from strength to strength,” King adds. “Their collective experience, acumen and energy is remarkable and I anticipate the group accomplishing a great deal in the years ahead.”

Please see the news release attached as Schedule “A” for a full description of the material change.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on Subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not applicable.

Item 8 Executive Officer

The name and business number of the executive officers of the Company who are knowledgeable of the material change and this report are:

Susan Chapelle or Tim Moore
Co-Chief Executive Officers
Telephone – 604-359-0060

Item 9 Date of Report

December 1, 2020

SCHEDULE "A"



Havn Life attracts international drug science and policy expert, joins UK policy reform group

Havn Life has joined the UK-based Conservative Drug Policy Reform Group (CDPRG), a group organized to benefit drug policy-making

The Havn Life Advisory Board adds Mr. King, a vocal advocate for drug policy reform and research.

December 1, 2020

Vancouver, BC - Havn Life Sciences Inc. (CSE : [HAVN](#)) (FSE : [5NP](#)) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has become a voting member of the [Conservative Drug Policy Reform Group](#) (CDPRG).

The Company is also pleased to announce that David King, director of research for CDPRG, has joined the Havn Life advisory board. King has co-authored several CDPRG white papers including 'The UK Review of Medicinal Cannabis: The Needs of a Nation' and 'The Medicinal Use of Psilocybin: A call for reform.' This year, King received the Dr Abbas Khan Medal by King's College London for 'outstanding humanitarian contributions to the service of society'.

He is also a founder of the Breaking Convention, Europe's largest academic conference on psychedelic drug research, and was a founding director of the Breaking Convention charity from 2010 to 2019.

The CDPRG is a UK-based organization that assembles evidence from across the fields of medicine, law-enforcement, economics, ethics, criminology and human rights, for the benefit of drug policy-making. This year the CDPRG launched a campaign to reschedule psilocybin in the UK as part of their mission to provide greater access for research and medicinal purposes. Havn Life will commission 250 hours of work from CDPRG's researchers.

"Being a part of the CDPRG global network of scientists allows us to utilize multidisciplinary expertise to develop psilocybin protocols that can have global impact," says Tim Moore, Havn Life CEO. "Collaboration across fields allows us to move the needle. We are building a strong foundation of knowledge to develop a safe and reliable supply of naturally-derived psychedelic compounds for research".

"As the clinical trial evidence for psychedelic therapies grows, it becomes increasingly clear that these interventions are safe, well-tolerated, and have the potential to change lives for the better, sometimes after only a single session," says King. "We do not yet know what the real-world impact of these therapies will be, but there are good reasons to believe that we will be better equipped to treat some of the most difficult and burdensome conditions of the modern age, for which new approaches are desperately needed."



King completed his undergraduate degree in medical anthropology in 2011, with a research thesis on beliefs and attitudes to health, illness and medicine among cannabis-using populations. He has also worked as a researcher at the Beckley Foundation and in immunology at the National University of Singapore. King was the founding President of both the award-winning Psychedelics Society at the University of Kent and the Society for Psychedelic Studies at King's College London.

King first met Havn Life Chief Psychedelic Officer Dr. Ivan Casselman when they both were students together at the School of Anthropology and Conservation, University of Kent, over ten years ago.

"I am delighted to be working with Dr. Casselman and the other members of the Havn Life team as they move from strength to strength," King adds. "Their collective experience, acumen and energy is remarkable and I anticipate the group accomplishing a great deal in the years ahead."

On Behalf of The Board of Directors

Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on [Facebook](#), [Twitter](#) and [Instagram](#).



Contact:

Investor Relations: ir@havnlife.com 604 687 7130
Media: brittany@exvera.com 778 238 6096

Forward-Looking Information: *This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable,*



there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

